<- Go Home
Camp4 Therapeutics Corporation
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Market Cap
$192.2M
Volume
329.1K
Cash and Equivalents
$75.3M
EBITDA
-$51.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$36.0M
Profit Margin
947.90%
52 Week High
$10.80
52 Week Low
$1.30
Dividend
N/A
Price / Book Value
3.28
Price / Earnings
-1.63
Price / Tangible Book Value
3.28
Enterprise Value
$123.3M
Enterprise Value / EBITDA
-2.58
Operating Income
-$53.3M
Return on Equity
172.70%
Return on Assets
-61.85
Cash and Short Term Investments
$75.3M
Debt
$6.3M
Equity
$58.7M
Revenue
$3.8M
Unlevered FCF
-$31.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium